Spironolactone for Ménière's Disease
Spironolactone is not recommended as a standard treatment for Ménière's disease, as it is not mentioned in current clinical practice guidelines and lacks evidence supporting its efficacy for this condition.
Guideline-Based Treatment Approach
The 2020 AAO-HNS clinical practice guideline for Ménière's disease provides a clear treatment hierarchy that does not include spironolactone 1:
First-Line Management (Least Aggressive)
- Dietary modifications:
- Low-sodium diet (1500-2300 mg daily)
- Limit alcohol consumption
- Limit caffeine intake
Second-Line Medical Management
- Diuretics are mentioned generically as "medications that remove excess body fluid" 1
- Antivertigo medications for acute attacks
- Antihistamines
- Betahistine (histamine analogue)
Progressive Interventions
- Vestibular rehabilitation
- Hearing aids
- Middle ear injections (steroids or gentamicin)
- Surgical options (endolymphatic sac decompression, vestibular nerve section, labyrinthectomy)
Why Spironolactone Is Not Recommended
The absence of spironolactone from the 2020 AAO-HNS guideline—the highest quality and most recent guideline for Ménière's disease—is significant. When guidelines mention "diuretics" for Ménière's disease, they typically refer to thiazide or loop diuretics combined with potassium-sparing agents, not spironolactone specifically 1.
Theoretical Concerns
The available research actually suggests spironolactone may be counterproductive for inner ear disorders. A 2002 study demonstrated that spironolactone blocked glucocorticoid-mediated hearing preservation in autoimmune mice, suggesting it interferes with mineralocorticoid receptor activity that may be protective for cochlear function 2. While this was in autoimmune hearing loss rather than Ménière's disease, it raises concerns about using mineralocorticoid receptor antagonists for inner ear pathology.
If Considering Off-Label Use
Should a clinician consider spironolactone despite the lack of guideline support, the FDA-approved dosing and monitoring would apply 3:
Dosing (extrapolated from edema indications)
- Start at 25 mg daily
- May increase to 50-100 mg daily if tolerated
- Take consistently with or without food
Critical Monitoring Requirements
- Serum potassium within 1 week of initiation or dose change, then regularly thereafter 3
- Monitor for hyperkalemia (increased risk with renal impairment)
- Periodic monitoring of electrolytes, renal function, uric acid, and blood glucose 3
- Watch for gynecomastia (dose-dependent, occurs in ~9% of males) 3
- Monitor for hypotension and volume depletion 3
Contraindications and Cautions
- Avoid in patients with impaired renal function (eGFR <30 mL/min/1.73 m²)
- Avoid concomitant potassium supplementation or potassium-sparing drugs
- Use caution with ACE inhibitors, ARBs, NSAIDs 3
Clinical Bottom Line
Follow the evidence-based treatment algorithm from the 2020 AAO-HNS guideline 1. Start with dietary sodium restriction (1500-2300 mg daily), limit alcohol and caffeine, and if diuretics are needed, use those with established evidence rather than spironolactone. Progress through the treatment hierarchy based on symptom control, reserving more aggressive interventions (intratympanic injections, surgery) for medically refractory cases 4.